Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | Magrolimab with Azacitidine | Myelodyspastic syndrome and acute myeloid leukemia (AML) | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Gilead Sciences Inc. | Lenacapavir - (CALIBRATE) | HIV | Phase 2 | Trial Completed | Subcutaneous | Anti-HIV |
| Gilead Sciences Inc. | Lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) - (PURPOSE-5) | Long-acting HIV prevention | Phase 2 | Ongoing | Lenacapavir is administered subcutaneously F/TDF is administered orally | Anti-HIV |
| Gilead Sciences Inc. | Islatravir (MK-8591D) and Lenacapavir - (ISLEND) | Human immunodeficiency virus (HIV) | Phase 3 | Ongoing | Oral | Anti-HIV |
| Gilead Sciences Inc. | Filgotinib - (PENGUIN) | Psoriatic arthritis | Phase 3 | Trial Discontinued | Oral | Immunology: Anti-TNF |
| Gilead Sciences Inc. | Lenacapavir - (PURPOSE 2) | HIV PreP | Phase 3 | Data Released | Subcutaneous injection | Anti-HIV |
| Gilead Sciences Inc. | TRODELVY (sacituzumab govitecan-hziy) - (ASCENT-07) | Refractory metastatic triple-negative breast cancer (TNBC) | Phase 3 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Hepcludex (Bulevirtide) - (MYR301) | Hepatitis delta virus (HDV) | BLA Filing | Data Released | Subcutaneous | Antiviral |
